Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Purchases $48,015.00 in Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel bought 5,500 shares of the stock in a transaction on Friday, April 4th. The stock was purchased at an average cost of $8.73 per share, for a total transaction of $48,015.00. Following the acquisition, the chief executive officer now owns 5,558,002 shares of the company’s stock, valued at $48,521,357.46. This trade represents a 0.10 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Snehal Patel also recently made the following trade(s):

• On Monday, April 7th, Snehal Patel bought 3,600 shares of Greenwich LifeSciences stock. The shares were acquired at an average price of $9.10 per share, with a total value of $32,760.00.
• On Friday, January 10th, Snehal Patel purchased 2,500 shares of Greenwich LifeSciences stock. The shares were purchased at an average price of $12.51 per share, with a total value of $31,275.00.
• On Tuesday, January 7th, Snehal Patel bought 1,800 shares of Greenwich LifeSciences stock. The stock was bought at an average price of $13.75 per share, with a total value of $24,750.00.

Greenwich LifeSciences Trading Up 4.0 %

Shares of NASDAQ:GLSI opened at $9.43 on Thursday. Greenwich LifeSciences, Inc. has a 12-month low of $8.06 and a 12-month high of $18.75. The business’s fifty day simple moving average is $11.34 and its 200-day simple moving average is $12.62. The company has a market capitalization of $123.96 million, a PE ratio of -11.79 and a beta of 1.76.

Institutional Trading of Greenwich LifeSciences

Several large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its holdings in shares of Greenwich LifeSciences by 4.6% in the 3rd quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock valued at $1,919,000 after buying an additional 5,861 shares during the period. Northern Trust Corp raised its holdings in Greenwich LifeSciences by 17.3% in the 4th quarter. Northern Trust Corp now owns 87,423 shares of the company’s stock worth $982,000 after purchasing an additional 12,923 shares during the period. State Street Corp raised its holdings in shares of Greenwich LifeSciences by 4.4% during the third quarter. State Street Corp now owns 71,408 shares of the company’s stock valued at $1,026,000 after acquiring an additional 3,005 shares during the last quarter. Garden State Investment Advisory Services LLC acquired a new position in shares of Greenwich LifeSciences during the third quarter valued at approximately $253,000. Finally, Rhumbline Advisers raised its holdings in shares of Greenwich LifeSciences by 48.7% during the first quarter. Rhumbline Advisers now owns 9,673 shares of the company’s stock valued at $92,000 after acquiring an additional 3,168 shares during the last quarter. Hedge funds and other institutional investors own 4.16% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $38.00 price target on shares of Greenwich LifeSciences in a research note on Tuesday, February 11th.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.